Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct 27;35(45):6228-6237.
doi: 10.1016/j.vaccine.2017.09.014. Epub 2017 Sep 26.

A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

Prasad S Kulkarni  1 , Sajjad Desai  2 , Tushar Tewari  3 , Anand Kawade  4 , Nidhi Goyal  5 , Bishan Swarup Garg  6 , Dinesh Kumar  7 , Suman Kanungo  8 , Veena Kamat  9 , Gagandeep Kang  10 , Ashish Bavdekar  4 , Sudhir Babji  10 , Sanjay Juvekar  4 , Byomkesh Manna  8 , Shanta Dutta  8 , Rama Angurana  7 , Deepika Dewan  7 , Abhijeet Dharmadhikari  2 , Jagdish K Zade  2 , Rajeev M Dhere  2 , Alan Fix  11 , Maureen Power  11 , Vidyasagar Uprety  3 , Varsha Parulekar  12 , Iksung Cho  11 , Temsunaro R Chandola  5 , Vikash K Kedia  5 , Abhishek Raut  6 , Jorge Flores  11 ; SII BRV-PV author group
Collaborators, Affiliations
Clinical Trial

A randomized Phase III clinical trial to assess the efficacy of a bovine-human reassortant pentavalent rotavirus vaccine in Indian infants

Prasad S Kulkarni et al. Vaccine. .

Abstract

Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, resulting in enormous morbidity, mortality, and economic burden. A bovine-human reassortant pentavalent rotavirus vaccine (BRV-PV) targeting the globally most common strains was developed in India and tested in a randomized, double-blind, placebo-controlled end-point driven Phase III efficacy clinical trial implemented at six sites across India. Infants 6 to 8weeks of age were randomized (1:1) to receive three oral doses of BRV-PV or placebo at 6, 10, and 14weeks of age along with routine vaccines. Home visit surveillance was conducted to detect severe rotavirus gastroenteritis (SRVGE) and safety outcomes until the children reached two years of age. A total of 3749 infants received BRV-PV while 3751 received placebo. At the time of the primary end-point (when the minimum number of cases needed for analysis were accrued) the vaccine efficacy against SRVGE was 36% (95% CI 11.7, 53.6, p=0.0067) in the per protocol (PP) analysis, and 41.9% (95% CI 21.1, 57.3, p=0.0005) in the intent to treat (ITT) analysis. Vaccine efficacy over the entire follow-up period (until children reached two years of age) was 39.5% (95% CI 26.7, 50, p<0.0001) in the PP analysis and 38.8% (95% CI, 26.4, 49, p<0.0001) in the ITT analysis. Vaccine efficacy against the very severe rotavirus cases (VSRVGE, Vesikari score≥16) was 60.5% (95% CI 17.7, 81, p=0.0131) at the time of the primary analysis and 54.7% (95% CI 29.7, 70.8, p=0.0004) for the complete follow-period in the PP population. The incidence of solicited, unsolicited, and serious adverse events were similar in both the vaccine and placebo groups. Likewise, the number of intussusceptions and deaths were similar between both groups. Thus, BRV-PV is an effective, well tolerated and safe vaccine in Indian infants. (Trial registration: Clinical Trials.Gov [NCT 02133690] and Clinical Trial Registry of India [CTRI/2013/05/003667]).

Trial registration: ClinicalTrials.gov NCT02133690.

Keywords: Efficacy; Infants; Rotavirus gastroenteritis; Safety; Vaccine.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flowchart.
Fig. 2
Fig. 2
Relationship between Vesikari severity score and corresponding vaccine efficacy.
See this image and copyright information in PMC

References

    1. Tate JE, Burton AH, Boschi-Pinto C, Parashar UD. World Health organization–coordinated global rotavirus surveillance network. Global, regional, and national estimates of rotavirus mortality in children 5 years of age, 2000–2013. Clin Infect Dis 2016;62(Suppl. 2):S96–S105. - PMC - PubMed
    1. John J., Sarkar R., Muliyil J., Bhandari N., Bhan M.K., Kang G. Rotavirus gastroenteritis in India, 2011–2013: revised estimates of disease burden and potential impact of vaccines. Vaccine. 2014;32(Suppl 1):A5–A9. - PubMed
    1. Rotavirus webpage. World Health Organization website. Available at: http://www.who.int/immunization/diseases/rotavirus/en/ [date accessed April 14, 2017].
    1. Global Advisory Committee on Vaccine Safety, 11–12 June 2014. Wkly Epidemiol Rec 2014;89(29):325–35. - PubMed
    1. Bhandari N., Rongsen-Chandola T., Bavdekar A. Efficacy of a monovalent human-bovine (116E) rotavirus vaccine in Indian infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2014;383(9935):2136–2143. - PMC - PubMed

Publication types

MeSH terms

Associated data